Owlstone Medical Wins Business Innovation Award for Breath Biopsy® Technology
Cambridge News & Media Business Excellence Awards 2017
Cambridge, UK, 24 March 2017: Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, has won the Business Innovation Award in the Cambridge News & Media Business Excellence Awards. The honour was announced last night (23 March 2017) at a presentation ceremony held in the Great Hall at King’s College, Cambridge, where guests heard from speaker Justin Webb, presenter of BBC Radio Four’s Today Programme.
Richard Duxbury, managing director of Cambridge News and Media, said: “These awards are held to celebrate these fantastic businesses and business people who make our region the place it is. No-one will have quite predicted the events of the last 12 months, but what stands out now is the incredible resilience and can-do attitude of our local business community. This year saw more entries than any time since our launch in 1994. The record number reflects the increasing popularity and continued credibility of these awards and the ongoing success of our local businesses and business people.”
Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “We are delighted to have received the accolade for Business Innovation in this year’s Business Excellence Awards. Our vision is to save 100,000 lives and $1.5 billion in healthcare costs by developing our breathalyzer for disease to enable diagnosis of cancer and other diseases earlier than existing tests. This allows for more effective treatment, reduced treatment costs, and ultimately, better patient survival rates.”
To find out more about Owlstone Medical visit: www.owlstonemedical.com
Notes to Editors
For a high resolution images please contact email@example.com
For more information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730 919
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.
The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.
Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.
Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, Owlstone Inc is a profitable business selling its proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.
Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.